Drug name - Aristada

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(8 years from now)

EP2445502B1 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445502A1 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445343A1 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

EP2445343B1 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

EP2445502A4 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445343A4 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders Jun, 2030

(7 years from now)

US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters Mar, 2032

(9 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters Nov, 2032

(10 years from now)

US11097006 ALKERMES INC Pharmaceutical compositions having improved storage stability Oct, 2033

(11 years from now)

US9193685 ALKERMES INC Pharmaceutical compositions having improved storage stability Oct, 2033

(11 years from now)

US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous intramuscular injection; treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
441MG/1.6ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
662MG/2.4ML (275.83MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
882MG/3.2ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1064MG/3.9ML (272.82MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.